EP Patent

EP4692048A3 — Methods of treating cdkl5 disorders with the compound ov329

Assigned to Ovid Therapeutics Inc · Expires 2026-04-01 · 0y expired

What this patent protects

A pharmaceutical composition comprising (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof for use in treating a infantile spasms in a subject is provided, wherein the composition is indicated to supply to the subject…

USPTO Abstract

A pharmaceutical composition comprising (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof for use in treating a infantile spasms in a subject is provided, wherein the composition is indicated to supply to the subject an amount of from 0.01 mg to 75 mg of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.

Drugs covered by this patent

Patent Metadata

Patent number
EP4692048A3
Jurisdiction
EP
Classification
Expires
2026-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Ovid Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.